Search

everythinglearnresearchcommunity

for

Search:↓

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.

The conversation humorously suggests that the hair loss industry, referred to as "Big Bald," deliberately delays a cure to profit from ongoing treatments like minoxidil, finasteride, and dutasteride. Participants debate whether a cure would be more profitable than current treatments, with some suggesting that the industry prefers continuous treatments for sustained profit.

UCLA's PP405 shows promise in reactivating dormant hair follicles for hair loss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.

A 19-year-old is experiencing hair loss and considering treatments like finasteride, oral minoxidil, and possibly dutasteride. Users suggest continuing with finasteride and minoxidil, with some recommending dutasteride for stronger results.

Microneedling may enhance hair regrowth by transferring stem cells to dormant follicles, improving the effects of minoxidil. Users discuss using microneedling with needle lengths around 1.5mm to stimulate hair growth.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

Switching from finasteride to dutasteride for treating hair loss, with reports of improved regrowth and little to no side effects.

Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.

PP405 may not need daily use like minoxidil, but finasteride might still be needed to maintain hair regrowth. PP405 reawakens dormant hair follicles, potentially offering a long-term solution, though not a permanent cure.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

The user switched from finasteride to dutasteride for hair loss but faced increased shedding and anxiety, regretting not staying with finasteride longer. Other users shared mixed experiences, advising patience with dutasteride, as it may take up to a year to show results.

The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

Hair loss treatments discussed include dermarolling, minoxidil, finasteride, and RU58841. Some users find dermarolling sad, while others mention the complexity of biological systems and limited research funding for hair loss.

A YouTuber named Kevin, also known as Rider_Of_Roach, who deleted his YouTube channel due to personal attacks and controversy surrounding his views on hair loss treatments. He advocated for FDA-approved treatments like finasteride and minoxidil but faced backlash from those who disagreed with him. The conversation also discusses his past trolling behavior and a lawsuit he filed against a website that published false information about him. Despite some disagreements, many viewers appreciated his research-based content and hope to see him return in the future.

Creatine might speed up hair loss in some people, especially those prone to male pattern baldness, but results differ. Some users experience no hair loss when using finasteride or dutasteride alongside creatine.

DHT affects hair follicles, contributing to hair loss, but the exact mechanism is unclear. Treatments like finasteride and minoxidil are used to manage hair loss, though they may have side effects and varying effectiveness.

A 25-year-old male with 10 years of hair loss is using minoxidil and considering adding finasteride or dutasteride, possibly with microneedling, to improve hair regrowth before a hair transplant. Community members suggest starting a DHT blocker immediately, considering oral minoxidil, and addressing low vitamin D and HDL levels.

A double blind, placebo-controlled study that looked into the potential effectiveness of topical fluridil for treating male androgenetic alopecia, showing increased anagen to telogen ratios with no reported side effects on libido or sexual performance.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

The conversation is about using RU58841 for hair loss, discussing the stability of the powder form and the need for a carrier solution like KB or PG + ethanol. The user is advised to mix RU58841 with stemoxydine and store it properly, while also considering safety precautions.

Finasteride may be losing effectiveness for the user after 4.5 years, possibly due to intense workouts or a synchronized hair shedding cycle. Suggestions include switching to Dutasteride or continuing with Finasteride while considering a hair transplant for hairline density.